Intranasal Vaccine

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.

Mansukh Manadaviya said that the world's first intranasal vaccine for Covid-19 iNCOVACC launched is a testimony to the innovative zeal of our scientists and a display of India's research and innovation prowess under the leadership of PM Modi.

iNCOVACC, the world's first COVID-19 intranasal vaccine, will be launched on January 26. The intranasal coronavirus vaccine has been developed by India's Bharat Biotech.

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.

The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.

Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.

Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.

Researchers have developed an intranasal anti-viral treatment for COVID-19 that decreases the amount of SARS-CoV-2 shed from infected animals and limits transmission of the virus.

Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.

Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.

An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.

Mansukh Manadaviya said that the world's first intranasal vaccine for Covid-19 iNCOVACC launched is a testimony to the innovative zeal of our scientists and a display of India's research and innovation prowess under the leadership of PM Modi.

iNCOVACC, the world's first COVID-19 intranasal vaccine, will be launched on January 26. The intranasal coronavirus vaccine has been developed by India's Bharat Biotech.

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.

The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.

Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.

Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.

Researchers have developed an intranasal anti-viral treatment for COVID-19 that decreases the amount of SARS-CoV-2 shed from infected animals and limits transmission of the virus.

Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.

Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.

An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.